Recent submissions

  • Night shift work and risk of breast cancer in women: the Generations Study cohort. 

    Jones, ME; Schoemaker, MJ; McFadden, EC; Wright, LB; Johns, LE; Swerdlow, AJ (2019-05-29)
    BACKGROUND: It is plausible that night shift work could affect breast cancer risk, possibly by melatonin suppression or circadian clock disruption, but epidemiological evidence is inconclusive. METHODS: Using serial ...
  • Dissecting PARP inhibitor resistance with functional genomics. 

    Pettitt, SJ; Lord, CJ (2019-04-04)
    The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. ...
  • Beyond DNA repair: the novel immunological potential of PARP inhibitors. 

    Chabanon, RM; Soria, J-C; Lord, CJ; Postel-Vinay, S (2019)
    Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, ...
  • Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development. 

    Drosopoulos, K; Linardopoulos, S (2019)
    Cellular models for siRNA and small molecule high-throughput screening have been widely used in the last decade to identify targets for drug discovery. As an example, we present a twofold readout approach based on cell ...
  • Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. 

    Sestak, I; Martín, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodríguez-Lescure, A; Gnant, M (2019-04-30)
    PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...
  • Targeting the PI3-kinase pathway in triple negative breast cancer. 

    Pascual, J; Turner, NC (2019-05-03)
    Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the PI3 kinase and AKT signalling pathway is one of the most frequent ...
  • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

    Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
    Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
  • Molecular residual disease and adjuvant trials design in solid tumors. 

    Coakley, M; Garcia-Murillas, I; Turner, NC (2019-05-14)
    Advances in diagnosis and treatment have resulted in a high rate of survival for many patients with early stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent ...
  • Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. 

    Diéras, V; Rugo, HS; Schnell, P; Gelmon, K; Cristofanilli, M; Loi, S; Colleoni, M; Lu, DR; Mori, A; Gauthier, E; Huang Bartlett, C; Slamon, DJ; Turner, NC; Finn, RS (2019-04-01)
    BACKGROUND: Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was assessed separately for three PALOMA studies. This study analyzed pooled, longer-term PALOMA safety ...
  • BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. 

    Turner, NC; Alarcón, E; Armstrong, AC; Philco, M; López Chuken, YA; Sablin, M-P; Tamura, K; Gómez Villanueva, A; Pérez-Fidalgo, JA; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Lindemann, JPO; Maudsley, R; Moschetta, M; Outhwaite, E; Pass, M; Rugman, P; Schiavon, G; Oliveira, M (2019-05-01)
    BACKGROUND: BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with the first-line weekly paclitaxel for advanced or metastatic estrogen receptor-positive ...
  • Accountability in the NHS: the impact on cancer care. 

    Macklin-Doherty, A (2018)
    Accountability of service delivery is becoming increasingly complex and never has this been more apparent than in the field of Oncology. Cancer care has an unrivalled level of complexity not only in the heterogeneity of ...
  • Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. 

    Clendenen, TV; Ge, W; Koenig, KL; Afanasyeva, Y; Agnoli, C; Brinton, LA; Darvishian, F; Dorgan, JF; Eliassen, AH; Falk, RT; Hallmans, G; Hankinson, SE; Hoffman-Bolton, J; Key, TJ; Krogh, V; Nichols, HB; Sandler, DP; Schoemaker, MJ; Sluss, PM; Sund, M; Swerdlow, AJ; Visvanathan, K; Zeleniuch-Jacquotte, A; Liu, M (2019-03-19)
    BACKGROUND: Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a ...
  • Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach. 

    Leal, MF; Haynes, BP; MacNeill, FA; Dodson, A; Dowsett, M (2019-06)
    PURPOSE: We evaluated whether multiplex protein quantification using antibody bar-coding with photocleavable oligonucleotides (NanoString) can be applied to evaluate protein expression in breast cancer FFPE specimens. We ...
  • Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. 

    Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; Gonzales-de-Castro, D; O'Leary, B; Garcia-Murillas, I; Bhide, S; Hubank, M; Harrington, K; Kim, D; Newbold, K (2018-11)
    BACKGROUND: Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ...
  • ESR1 mutations in metastatic lobular breast cancer patients. 

    Desmedt, C; Pingitore, J; Rothé, F; Marchio, C; Clatot, F; Rouas, G; Richard, F; Bertucci, F; Mariani, O; Galant, C; Fribbens, C; O'Leary, B; van den Eynden, G; Salgado, R; Turner, NC; Piccart, M; Vincent-Salomon, A; Pruneri, G; Larsimont, D; Sotiriou, C (2019)
    Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer after invasive ductal breast cancer (IDC), accounts for up to 15% of all invasive cases and generally express the estrogen ...
  • Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. 

    Turner, NC; Liu, Y; Zhu, Z; Loi, S; Colleoni, M; Loibl, S; DeMichele, A; Harbeck, N; André, F; Bayar, MA; Michiels, S; Zhang, Z; Giorgetti, C; Arnedos, M; Huang Bartlett, C; Cristofanilli, M (2019-05-10)
    PURPOSE: A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. METHODS: The PALOMA-3 ( ClinicalTrials.gov identifier: NCT01942135) ...
  • Genome-wide association study of germline variants and breast cancer-specific mortality. 

    Escala-Garcia, M; Guo, Q; Dörk, T; Canisius, S; Keeman, R; Dennis, J; Beesley, J; Lecarpentier, J; Bolla, MK; Wang, Q; Abraham, J; Andrulis, IL; Anton-Culver, H; Arndt, V; Auer, PL; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bernstein, L; Blomqvist, C; Boeckx, B; Bojesen, SE; Bonanni, B; Børresen-Dale, A-L; Brauch, H; Brenner, H; Brentnall, A; Brinton, L; Broberg, P; Brock, IW; Brucker, SY; Burwinkel, B; Caldas, C; Caldés, T; Campa, D; Canzian, F; Carracedo, A; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chenevix-Trench, G; Cheng, T-YD; Chin, S-F; Clarke, CL; NBCS Collaborators; Cordina-Duverger, E; Couch, FJ; Cox, DG; Cox, A; Cross, SS; Czene, K; Daly, MB; Devilee, P; Dunn, JA; Dunning, AM; Durcan, L; Dwek, M; Earl, HM; Ekici, AB; Eliassen, AH; Ellberg, C; Engel, C; Eriksson, M; Evans, DG; Figueroa, J; Flesch-Janys, D; Flyger, H; Gabrielson, M; Gago-Dominguez, M; Galle, E; Gapstur, SM; García-Closas, M; García-Sáenz, JA; Gaudet, MM; George, A; Georgoulias, V; Giles, GG; Glendon, G; Goldgar, DE; González-Neira, A; Alnæs, GIG; Grip, M; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Hankinson, S; Harkness, EF; Harrington, PA; Hart, SN; Hartikainen, JM; Hein, A; Hillemanns, P; Hiller, L; Holleczek, B; Hollestelle, A; Hooning, MJ; Hoover, RN; Hopper, JL; Howell, A; Huang, G; Humphreys, K; Hunter, DJ; Janni, W; John, EM; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kabisch, M; Kaczmarek, K; Kerin, MJ; Khan, S; Khusnutdinova, E; Kiiski, JI; Kitahara, CM; Knight, JA; Ko, Y-D; Koppert, LB; Kosma, V-M; Kraft, P; Kristensen, VN; Krüger, U; Kühl, T; Lambrechts, D; Le Marchand, L; Lee, E; Lejbkowicz, F; Li, L; Lindblom, A; Lindström, S; Linet, M; Lissowska, J; Lo, W-Y; Loibl, S; Lubiński, J; Lux, MP; MacInnis, RJ; Maierthaler, M; Maishman, T; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martinez, ME; Mavroudis, D; McLean, C; Meindl, A; Middha, P; Miller, N; Milne, RL; Moreno, F; Mulligan, AM; Mulot, C; Nassir, R; Neuhausen, SL; Newman, WT; Nielsen, SF; Nordestgaard, BG; Norman, A; Olsson, H; Orr, N; Pankratz, VS; Park-Simon, T-W; Perez, JIA; Pérez-Barrios, C; Peterlongo, P; Petridis, C; Pinchev, M; Prajzendanc, K; Prentice, R; Presneau, N; Prokofieva, D; Pylkäs, K; Rack, B; Radice, P; Ramachandran, D; Rennert, G; Rennert, HS; Rhenius, V; Romero, A; Roylance, R; Saloustros, E; Sawyer, EJ; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schumacher, F; Schwentner, L; Scott, RJ; Scott, C; Seynaeve, C; Shah, M; Simard, J; Smeets, A; Sohn, C; Southey, MC; Swerdlow, AJ; Talhouk, A; Tamimi, RM; Tapper, WJ; Teixeira, MR; Tengström, M; Terry, MB; Thöne, K; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Turman, C; Turnbull, C; Ulmer, H-U; Untch, M; Vachon, C; van Asperen, CJ; van den Ouweland, AMW; van Veen, EM; Wendt, C; Whittemore, AS; Willett, W; Winqvist, R; Wolk, A; Yang, XR; Zhang, Y; Easton, DF; Fasching, PA; Nevanlinna, H; Eccles, DM; Pharoah, PDP; Schmidt, MK (2019-03)
    BACKGROUND: We examined the associations between germline variants and breast cancer mortality using a large meta-analysis of women of European ancestry. METHODS: Meta-analyses included summary estimates based on Cox models ...
  • CoverView: a sequence quality evaluation tool for next generation sequencing data. 

    Münz, M; Mahamdallie, S; Yost, S; Rimmer, A; Poyastro-Pearson, E; Strydom, A; Seal, S; Ruark, E; Rahman, N (2018)
    Quality assurance and quality control are essential for robust next generation sequencing (NGS). Here we present CoverView, a fast, flexible, user-friendly quality evaluation tool for NGS data. CoverView processes mapped ...

View more